Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V A Johnson

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
AIDS (London, England)|March 14, 2000
Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapyH M Precious, H F Günthard, J K Wong, et al.
The Australian & New Zealand Journal of Obstetrics & Gynaecology|August 1, 1994
Fetal pulse oximetry: a new method of monitoring the fetusN Johnson, V A Johnson, H McNamara, et al.
Antimicrobial Agents and Chemotherapy|December 31, 1998
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 InvestigatorsX J Zhou, L B Sheiner, R T D'Aquila, et al.
Nature|January 7, 1988
HIV infection is blocked in vitro by recombinant soluble CD4R A Fisher, J M Bertonis, W Meier, et al.
Nature|January 12, 1995
Viral dynamics in human immunodeficiency virus type 1 infectionX Wei, S K Ghosh, M E Taylor, et al.
The Journal of Infectious Diseases|January 3, 2001
Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infectionS A Call, M S Saag, A O Westfall, et al.
Biological Reviews of the Cambridge Philosophical Society|May 9, 2020
The role of the microbiome in the neurobiology of social behaviourAmar Sarkar, Siobhán Harty, Katerina V-A Johnson, et al.
Annals of Internal Medicine|August 1, 1996
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working PartyJ A Bartlett, S L Benoit, V A Johnson, et al.
The Journal of Infectious Diseases|May 1, 1995
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working GroupA J Japour, S Welles, R T D'Aquila, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1993
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working GroupA J Japour, D L Mayers, V A Johnson, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
AIDS (London, England)|March 14, 2000
Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapyH M Precious, H F Günthard, J K Wong, et al.
The Australian & New Zealand Journal of Obstetrics & Gynaecology|August 1, 1994
Fetal pulse oximetry: a new method of monitoring the fetusN Johnson, V A Johnson, H McNamara, et al.
Antimicrobial Agents and Chemotherapy|December 31, 1998
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 InvestigatorsX J Zhou, L B Sheiner, R T D'Aquila, et al.
Nature|January 7, 1988
HIV infection is blocked in vitro by recombinant soluble CD4R A Fisher, J M Bertonis, W Meier, et al.
Nature|January 12, 1995
Viral dynamics in human immunodeficiency virus type 1 infectionX Wei, S K Ghosh, M E Taylor, et al.
The Journal of Infectious Diseases|January 3, 2001
Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infectionS A Call, M S Saag, A O Westfall, et al.
Biological Reviews of the Cambridge Philosophical Society|May 9, 2020
The role of the microbiome in the neurobiology of social behaviourAmar Sarkar, Siobhán Harty, Katerina V-A Johnson, et al.
Annals of Internal Medicine|August 1, 1996
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working PartyJ A Bartlett, S L Benoit, V A Johnson, et al.
The Journal of Infectious Diseases|May 1, 1995
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working GroupA J Japour, S Welles, R T D'Aquila, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1993
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working GroupA J Japour, D L Mayers, V A Johnson, et al.
Pageof 10